Page 27 - CJO_F18

REVIEW

51. Dell SJ, Lowry GM, Northcutt JA, Howes J, Novack GD, Hart K. hydrochloride 0.1% ophthalmic solution and ketotifen fumarate
A randomized, double-masked, placebo-controlled parallel study 0.025% ophthalmic solution in the conjunctival antigen challenge
of 0.2% loteprednol etabonate in patients with seasonal allergic model. Clin Ther 2000;22:826-33.
conjunctivitis. J Allergy Clin Immunol 1998;102:251-5. 63. Williams JI, Kennedy KS, Gow JA, et al. Prolonged effectiveness
52. Shulman DG, Lothringer LL, Rubin JM, et al. A randomized, of bepotastine besilate ophthalmic solution for the treatment of
double-masked, placebo-controlled parallel study of loteprednol ocular symptoms of allergic conjunctivitis. J Ocul Pharmacol Ther
etabonate 0.2% in patients with seasonal allergic conjunctivitis. 2011;27:385-93.
Ophthalmology 1999;106:362-9. 64. Ilyas H, Slonim CB, Braswell GR, Favetta JR, Schulman M. Long-
53. Ballas Z, Blumenthal M, Tinkelman DG, Kriz R, Rupp G. Clinical term safety of loteprednol etabonate 0.2% in the treatment of
evaluation of ketorolac tromethamine 0.5% ophthalmic solution for seasonal and perennial allergic conjunctivitis. Eye Contact Lens
the treatment of seasonal allergic conjunctivitis. Surv Ophthalmol 2004;30:10-3.
1993;38 Suppl:141-8. 65. Comstock TL, Sheppard JD. Loteprednol etabonate for in-
54. Bielory L. Update on ocular allergy treatment. Expert Opin Pharma- flammatory conditions of the anterior segment of the eye:
cother 2002;3:541-53. Twenty years of clinical experience with a retrometabolically
55. Owen CG, Shah A, Henshaw K, Smeeth L, Sheikh A. Topical designed corticosteroid. Expert Opin Pharmacother 2018. doi:
treatments for seasonal allergic conjunctivitis: systematic review 10.1080/14656566.2018.1439920.
and meta-analysis of efficacy and effectiveness. Br J Gen Pract 66. Tauber J, Raizman MB, Ostrov CS, et al. A multicenter comparison
2004;54:451-6. of the ocular efficacy and safety of diclofenac 0.1% solution with
56. Abelson MB, Berdy GJ, Mundorf T, Amdahl LD, Graves AL, Pemi- that of ketorolac 0.5% solution in patients with acute seasonal al-
rolast study g. Pemirolast potassium 0.1% ophthalmic solution is an lergic conjunctivitis. J Ocul Pharmacol Ther 1998;14:137-45.
effective treatment for allergic conjunctivitis: a pooled analysis of 67. Yaylali V, Demirlenk I, Tatlipinar S, et al. Comparative study of 0.1%
two prospective, randomized, double-masked, placebo-controlled, olopatadine hydrochloride and 0.5% ketorolac tromethamine in the
phase III studies. J Ocul Pharmacol Ther 2002;18:475-88. treatment of seasonal allergic conjunctivitis. Acta Ophthalmol Scand
57. Allansmith MR, Ross RN. Ocular allergy and mast cell stabilizers. 2003 Aug;81(4):378-82.
Surv Ophthalmol 1986;30:229-44. 68. Celik T, Turkoglu EB. Comparative evaluation of olopatadine 0.01%
58. Manzouri B, Flynn TH, Larkin F, Ono SJ, Wyse R. Pharmacotherapy combined fluorometholone 0.1% treatment versus olopatadine
of allergic eye disease. Expert Opin Pharmacother 2006;7:1191-200. 0.01% combined ketorolac 0.4% treatment in patients with acute
59. Leonardi A, Abelson MB. Double-masked, randomized, placebo- seasonal allergic conjunctivitis. Curr Eye Res 2014;39:42-6.
controlled clinical study of the mast cell-stabilizing effects of treat- 69. Wan KH, Chen LJ, Rong SS, Pang CP, Young AL. Topical cyclospo-
ment with olopatadine in the conjunctival allergen challenge model rine in the treatment of allergic conjunctivitis: a meta-analysis.
in humans. Clin Ther 2003;25:2539-52. Ophthalmology 2013;120:2197-203.
60. Leonardi A, Zafirakis P. Efficacy and comfort of olopatadine versus 70. Fukushima A, Ohashi Y, Ebihara N, et al. Therapeutic effects of
ketotifen ophthalmic solutions: a double-masked, environmental 0.1% tacrolimus eye drops for refractory allergic ocular diseases
study of patient preference. Curr Med Res Opin 2004;20:1167-73. with proliferative lesion or corneal involvement. Br J Ophthalmol
61. Avunduk AM, Tekelioglu Y, Turk A, Akyol N. Comparison of the 2014;98:1023-7.
effects of ketotifen fumarate 0.025% and olopatadine HCl 0.1% 71. Moote W, Kim H. Allergen-specific immunotherapy. Allergy,
ophthalmic solutions in seasonal allergic conjunctivities: a 30-day, asthma, and clinical immunology : official journal of the Canadian
randomized, double-masked, artificial tear substitute-controlled Society of Allergy and Clinical Immunology. 2011;7 Suppl 1:S5.
trial. Clin Ther 2005;27:1392-402. 72. Berger WE, Granet DB, Kabat AG. Diagnosis and management of
62. Berdy GJ, Spangler DL, Bensch G, Berdy SS, Brusatti RC. A compar- allergic conjunctivitis in pediatric patients. Allergy Asthma Proc
ison of the relative efficacy and clinical performance of olopatadine 2017;38:16-27.

Eyeglasses & Accessories ™
2018 Catalogue Vol. 13
Customer ID #
Children's Supplies
2018 Catalogue now available.
Visual Aids
For a digital copy: www.whiteop.ca/wos.pdf White Ophthalmic Supply Lab Supplies
#3 - 5915 40 ST SE
Calgary, AB T2C 2H6
For a print copy please contact us by phone or email. Phone: 1-800-661-1562
(403) 293-3060
Fax: (403) 285-1487
Web: www.Whiteop.ca
Email: Orders@Whiteop.ca
HOURS OF OPERATIONS
Mon - Fri 8:00 am - 4:00 pm MST Eye Glass Tools & Repair
1-800-661-1562 orders@whiteop.ca Opticians, Optometrists and Ophthalmologists. 1
We accept:
Canada’s Coast to Coast Optical Supplier for

CANADIAN JOURNAL of OPTOMETRY | REVUE CANADIENNE D’OPTOMÉTRIE VOL. 80 NO. 3 27

38668_CJO_F18 August 10, 2018 8:58 AM APPROVAL: ___________________ DATE: ___________________